<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147958">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869387</url>
  </required_header>
  <id_info>
    <org_study_id>CRISOL-MARTINA-2013</org_study_id>
    <nct_id>NCT01869387</nct_id>
  </id_info>
  <brief_title>Respiratory Muscle Function in COPD Exacerbations</brief_title>
  <official_title>Improvement of Respiratory Muscle Function With Noninvasive Ventilation in Exacerbated COPD Patients Presenting Hypercapnic Respiratory Failure Without Acidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that noninvasive mechanical ventilation (NIV) is effective in the
      treatment of severe exacerbations of COPD presenting respiratory acidosis.

      The aim of the study is to evaluate the benefit of adding NIV to conventional treatment in
      patients with COPD exacerbation and hypercapnic respiratory failure without acidosis
      requiring hospital admission. It is known that NIV improves respiratory mechanics, so the
      primary outcome will be respiratory muscle function.

      All patients admitted to the hospital for COPD exacerbation and hypercapnic respiratory
      failure without acidosis will be included for a period of 12 months. The patients will be
      randomized into two groups (conventional treatment or conventional treatment plus NIV).
      Clinical data, blood gases, muscle strength parameters will be collected at the inclusion
      time and 24h after starting NIV. Quality of life and hospital stay will be measured at
      discharge. All patients will be followed for a year.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Respiratory muscle function.</measure>
    <time_frame>At baseline, at discharge (average of 8 days), 6 months and one year later.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of maximal inspiratory pressure and sniff nasal inspiratory pressure using a portable respiratory pressure meter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization.</measure>
    <time_frame>At discharge (average of 8 days).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea scale questionnaire</measure>
    <time_frame>At baseline, at discharge, 6 months and one year later.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At baseline, 6 months and one year later.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood gases</measure>
    <time_frame>At baseline and at discharge (average of 8 days).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital readmissions in the next year</measure>
    <time_frame>At one year after discharge (average of 8 days).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment consists in bronchodilator and  parenteral corticosteroids and oxygen therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment plus non-invasive ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive ventilation</intervention_name>
    <arm_group_label>Standard treatment plus non-invasive ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD according to international guidelines ( GOLD)

          -  COPD exacerbation requiring hospitalization

          -  Initial blood gases: PaCO2&gt; 50 mm Hg and pH&gt; 7.35.

          -  If the patient does not have COPD diagnosis at the time of inclusion, it  could  be
             included if the diagnosis is confirmed within three months after the  exacerbation.

        Exclusion Criteria:

          -  Patients with a pH below 7.35

          -  Patients with intubation criteria

          -  Other chronic respiratory diseases (fibrothorax, cystic fibrosis, significant
             ribcage alterations)

          -  Neuromuscular Diseases

          -  Significant associated chronic systemic diseases (severe liver disease, chronic renal
             failure requiring dialysis, severe heart disease and active neoplasia)

          -  COPD exacerbation secondary to pulmonary embolism, pneumonia or pneumothorax

          -  Patients in active treatment with CPAP or home ventilation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina Estirado, PhD</last_name>
    <phone>932483138</phone>
    <email>97623@parcdesalutmar.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital del Mar (Servei de Pneumología)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Estirado, PhD</last_name>
      <phone>0034932483138</phone>
      <email>97623@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Cristina Estirado, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
